Search research articles
Contact Us
Filters
Showing results (191-200 of 259) with videos related to
Page
of 26
Sort By:
Breast Care (Basel, Switzerland)
|
April 21, 2025
The Challenge of Calculating EUSOMA Quality Indicators with Administrative Data: A Pilot Study in Belgium
Roos Leroy, Cindy De Gendt, Jolyce Bourgeois, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2025
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial
Chiara Dauccia, Maria Alice Franzoi, Samuel Martel, et al.
The Oncologist
|
January 30, 2013
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience
Otto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2014
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab
Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, et al.
Breast (Edinburgh, Scotland)
|
February 14, 2026
Association between alcohol consumption and breast cancer incidence and prognosis: A systematic review and meta-analysis
Luca Arecco, Pedro M Cacilhas, Camila Bobato Lara Gismondi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Richard D Gelber, Xin V Wang, Bernard F Cole, et al.
The New England Journal of Medicine
|
January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Sara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 12, 2023
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis
Viola Salvestrini, Kyubo Kim, Saverio Caini, et al.
Breast Cancer Research and Treatment
|
September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
Evandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.
Page
of 26
Search research articles
Search
Showing results (191-200 of 259) with videos related to
Sort By:
Page
of 26
Breast Care (Basel, Switzerland)
|
April 21, 2025
The Challenge of Calculating EUSOMA Quality Indicators with Administrative Data: A Pilot Study in Belgium
Roos Leroy, Cindy De Gendt, Jolyce Bourgeois, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2025
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial
Chiara Dauccia, Maria Alice Franzoi, Samuel Martel, et al.
The Oncologist
|
January 30, 2013
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience
Otto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2014
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab
Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, et al.
Breast (Edinburgh, Scotland)
|
February 14, 2026
Association between alcohol consumption and breast cancer incidence and prognosis: A systematic review and meta-analysis
Luca Arecco, Pedro M Cacilhas, Camila Bobato Lara Gismondi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Richard D Gelber, Xin V Wang, Bernard F Cole, et al.
The New England Journal of Medicine
|
January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Sara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 12, 2023
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis
Viola Salvestrini, Kyubo Kim, Saverio Caini, et al.
Breast Cancer Research and Treatment
|
September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
Evandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.
Page
of 26